329 related articles for article (PubMed ID: 31326599)
1. An overview on chemical structures as ΔF508-CFTR correctors.
Spanò V; Montalbano A; Carbone A; Scudieri P; Galietta LJV; Barraja P
Eur J Med Chem; 2019 Oct; 180():430-448. PubMed ID: 31326599
[TBL] [Abstract][Full Text] [Related]
2. Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors.
Amico G; Brandas C; Moran O; Baroni D
Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31683989
[TBL] [Abstract][Full Text] [Related]
3. NBD2 Is Required for the Rescue of Mutant F508del CFTR by a Thiazole-Based Molecule: A Class II Corrector for the Multi-Drug Therapy of Cystic Fibrosis.
Brandas C; Ludovico A; Parodi A; Moran O; Millo E; Cichero E; Baroni D
Biomolecules; 2021 Sep; 11(10):. PubMed ID: 34680050
[TBL] [Abstract][Full Text] [Related]
4. Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening.
Pedemonte N; Lukacs GL; Du K; Caci E; Zegarra-Moran O; Galietta LJ; Verkman AS
J Clin Invest; 2005 Sep; 115(9):2564-71. PubMed ID: 16127463
[TBL] [Abstract][Full Text] [Related]
5. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
Yang H; Ma T
Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Fused Pyrrolothiazole Systems as Correctors of Mutant CFTR Protein.
Spanò V; Barreca M; Cilibrasi V; Genovese M; Renda M; Montalbano A; Galietta LJV; Barraja P
Molecules; 2021 Feb; 26(5):. PubMed ID: 33652850
[TBL] [Abstract][Full Text] [Related]
7. Cystic Fibrosis: Proteostatic correctors of CFTR trafficking and alternative therapeutic targets.
Hanrahan JW; Sato Y; Carlile GW; Jansen G; Young JC; Thomas DY
Expert Opin Ther Targets; 2019 Aug; 23(8):711-724. PubMed ID: 31169041
[No Abstract] [Full Text] [Related]
8. A chemical corrector modifies the channel function of F508del-CFTR.
Kim Chiaw P; Wellhauser L; Huan LJ; Ramjeesingh M; Bear CE
Mol Pharmacol; 2010 Sep; 78(3):411-8. PubMed ID: 20501743
[TBL] [Abstract][Full Text] [Related]
9. Proteostasis Regulators in Cystic Fibrosis: Current Development and Future Perspectives.
Brusa I; Sondo E; Falchi F; Pedemonte N; Roberti M; Cavalli A
J Med Chem; 2022 Apr; 65(7):5212-5243. PubMed ID: 35377645
[TBL] [Abstract][Full Text] [Related]
10. Elexacaftor Mediates the Rescue of F508del CFTR Functional Expression Interacting with MSD2.
Bongiorno R; Ludovico A; Moran O; Baroni D
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629017
[TBL] [Abstract][Full Text] [Related]
11. Correctors of the basic trafficking defect of the mutant F508del-CFTR that causes cystic fibrosis.
Birault V; Solari R; Hanrahan J; Thomas DY
Curr Opin Chem Biol; 2013 Jun; 17(3):353-60. PubMed ID: 23711435
[TBL] [Abstract][Full Text] [Related]
12. Correcting CFTR folding defects by small-molecule correctors to cure cystic fibrosis.
Mijnders M; Kleizen B; Braakman I
Curr Opin Pharmacol; 2017 Jun; 34():83-90. PubMed ID: 29055231
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of thiazole derivatives on basic defects underlying cystic fibrosis.
Pesce E; Pedemonte N; Leoni A; Locatelli A; Morigi R
Bioorg Med Chem Lett; 2020 Nov; 30(21):127473. PubMed ID: 32784089
[TBL] [Abstract][Full Text] [Related]
14. Synergy-based small-molecule screen using a human lung epithelial cell line yields ΔF508-CFTR correctors that augment VX-809 maximal efficacy.
Phuan PW; Veit G; Tan J; Roldan A; Finkbeiner WE; Lukacs GL; Verkman AS
Mol Pharmacol; 2014 Jul; 86(1):42-51. PubMed ID: 24737137
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and structure-activity relationship of aminoarylthiazole derivatives as correctors of the chloride transport defect in cystic fibrosis.
Pesce E; Bellotti M; Liessi N; Guariento S; Damonte G; Cichero E; Galatini A; Salis A; Gianotti A; Pedemonte N; Zegarra-Moran O; Fossa P; Galietta LJ; Millo E
Eur J Med Chem; 2015 Jun; 99():14-35. PubMed ID: 26041577
[TBL] [Abstract][Full Text] [Related]
16. Decoding F508del misfolding in cystic fibrosis.
Wang XR; Li C
Biomolecules; 2014 May; 4(2):498-509. PubMed ID: 24970227
[TBL] [Abstract][Full Text] [Related]
17. Partial Rescue of F508del-CFTR Stability and Trafficking Defects by Double Corrector Treatment.
Capurro V; Tomati V; Sondo E; Renda M; Borrelli A; Pastorino C; Guidone D; Venturini A; Giraudo A; Mandrup Bertozzi S; Musante I; Bertozzi F; Bandiera T; Zara F; Galietta LJV; Pedemonte N
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34067708
[TBL] [Abstract][Full Text] [Related]
18. CFTR: folding, misfolding and correcting the ΔF508 conformational defect.
Lukacs GL; Verkman AS
Trends Mol Med; 2012 Feb; 18(2):81-91. PubMed ID: 22138491
[TBL] [Abstract][Full Text] [Related]
19. HGF stimulation of Rac1 signaling enhances pharmacological correction of the most prevalent cystic fibrosis mutant F508del-CFTR.
Moniz S; Sousa M; Moraes BJ; Mendes AI; Palma M; Barreto C; Fragata JI; Amaral MD; Matos P
ACS Chem Biol; 2013 Feb; 8(2):432-42. PubMed ID: 23148778
[TBL] [Abstract][Full Text] [Related]
20. Probing conformational rescue induced by a chemical corrector of F508del-cystic fibrosis transmembrane conductance regulator (CFTR) mutant.
Yu W; Kim Chiaw P; Bear CE
J Biol Chem; 2011 Jul; 286(28):24714-25. PubMed ID: 21602569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]